Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms

Lambert, Max Norman Tandrup; Thorup, Anne Cathrine; Hansen, Esben Søvsø Szocska; Jeppesen, Per Bendix

doi:10.1371/journal.pone.0176590

Cited by 54 publications

(54 citation statements)

References 51 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Of these, 330 were excluded; 59 included fewer than 20 women per study arm and 54 were not an RCT; 126 did not clearly state a sample size calculation; 52 did not measure vasomotor symptoms as the primary outcome; 39 were secondary analysis. Following these exclusions, 214 RCT were included…”

Section: Resultsmentioning

confidence: 99%

“…Other subjective vasomotor symptoms measurement tools included a 20‐item structured symptom checklist; two of the items asking about the presence of hot flushes and cold/night sweats, a 5‐point (from none to very severe) scoring system about the severity of hot flushes and night sweats, Interactive Voice Response System to record the number and severity of the hot flushes, and self‐reported surveys . Objective measures of vasomotor symptoms such as skin conductance were used in five trials in addition to subjective measures (Table ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review

Iliodromiti

Wang

Lumsden

et al. 2019

BJOG

View full text Add to dashboard Cite

Background There is substantial variation in how menopausal vasomotor symptoms are reported and measured among intervention studies. This has prevented meaningful comparisons between treatments and limited data synthesis. Objectives To review systematically the outcome reporting and measures used to assess menopausal vasomotor symptoms from randomised controlled trials of treatments. Search strategy We searched MEDLINE, Embase, and Cochrane Central Register of Controlled Trials from inception to May 2018. Selection criteria Randomised controlled trials with a primary outcome of menopausal vasomotor symptoms in women and a sample size of at least 20 women per study arm. Data collection and analysis Data about study characteristics, primary vasomotor‐related outcomes and methods of measuring them. Main results The search identified 5591 studies, 214 of which were included. Forty‐nine different primary reported outcomes were identified for vasomotor symptoms and 16 different tools had been used to measure these outcomes. The most commonly reported outcomes were frequency (97/214), severity (116/214), and intensity (28/114) of vasomotor symptoms or a composite of these outcomes (68/214). There was little consistency in how the frequency and severity/intensity of vasomotor symptoms were defined. Conclusions There is substantial variation in how menopausal vasomotor symptoms have been reported and measured in treatment trials. Future studies should include standardised outcome measures which reflect the priorities of patients, clinicians, and researchers. This is most effectively achieved through the development of a Core Outcome Set. This systematic review is the first step towards development of a Core Outcome Set for menopausal vasomotor symptoms. Tweetable summary Menopausal hot flushes and night sweats have been reported in 49 different ways in clinical research. A core outcome set is urgently required.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review

Iliodromiti

Wang

Lumsden

et al. 2019

BJOG

View full text Add to dashboard Cite

show abstract

“…Peri-menopausal women subjects were supplemented with isoflavones and probiotics (34 mg/d isoflavones; probiotic combinations and dosage were not revealed in the study) for 12 w. The hot flush frequency (HFF), hot flush intensity, selfreported HFF, and hot flush severity, plasma lipids and blood pressure were measured. The results suggested that moderate intervention of red clover isoflavone and probiotics significantly reduced the self-reported vasomotor symptoms [44]. 9 CFU of L. crispatus LbV 88, 1 × 10 9 CFU of L. rhamnosus LbV 96, 0.2 × 10 9 CFU of L. ensenii LbV 116 and 0.3 × 10 9 CFU of L. gasseri LbV 150N) twice daily for two weeks.…”

Section: Probiotics and Menopausementioning

confidence: 92%

Influence of Probiotic Supplementation on Climacteric Symptoms in Menopausal Women-a Mini Review

2018

View full text Add to dashboard Cite

Menopause (MP) is a natural physiological event of woman’s life and is defined as the absence of menstrual periods for at least twelve months and loss of function of ovarian. The common symptoms of MP are irregular vaginal bleeding, hot flushes especially in head and chest, night sweats, insomnia, vaginal and urinary symptoms, cognitive dysfunction, increased cancer risk, osteopenia, high blood pressure, diabetes, and cardiovascular diseases. Microbiome has been associated with several health benefits. Probiotic supplementation helps to enhance the quality of microbiome thereby confers the health benefits to the host system. The microbiome, hormone (estrogen) changes, and probiotic intervention are related to the health status of the female reproductive system. The vaginal microbiome (VM) play a critical role in female reproductive health and MP, which can be greatly influenced by probiotics, and other medicine especially antibiotics and hormone therapy. The role of VM in supporting vaginal health is not clear and debatable. Understanding the role of vaginal Lactobacillus could expose the pathogenesis of vaginal dysbiosis, which helps to improve diagnostic and therapeutic strategies for several dysbiosis associated health issues and menopause-related symptoms. Recent studies suggested that the intervention of probiotic preparation with or without nutraceutical formulation (mostly with isoflavones) improve the health status of menopausal women. The mechanism of probiotics mediated health improvement in menopausal women is not yet described clearly. Several controversies are there on the link between probiotic, gut microbiota, vaginal microbiota, and estrogen deficit. The present review summarizes the influence of probiotic supplementation on climacteric symptoms in menopausal women. The literature search was made in Scopus, Google Scholar, PubMed using the keywords “probiotics” and “menopause”. The documents were carefully checked for the relevance to the current manuscript, and the selection was made without any restriction in the year of publication.

show abstract

“…Red clover can also reduce the intensity of other complaints from this period, but future studies are necessary in order to confirm the current knowledge [21]. Lambert et al suggested that red clover was more useful and also was superior to placebo in decreasing selfreported vasomotor disorders [30].…”

Section: The Management Of Vasomotor Disordersmentioning

confidence: 99%

Management Strategies of The Symptomatology and Pathology Associated with Menopause – An Overview

Bălan¹,

Dima²,

I³

et al. 2019

View full text Add to dashboard Cite

Menopause is a physiological period, considered to be installed after at least 12 months without menstruation. The mean age at menopause is 51 years. This condition is the consequence of hormonal imbalance that produces a series of general manifestations, which have become increasingly important and in most of the cases require treatment to improve. This paper aims to analyze all the therapeutical strategies applied for the improvement of the menopausal symptomatology. After a review of the last five years literature, we identified epidemiological studies, clinical cases, guidelines, and meta-analysis regarding the proper management strategies for the symptoms and pathologies associated with menopause. Fifty-three studies have been included in this paper that provides an overview of the impact of various menopause therapies. Vasomotor symptoms (VMS), hormonal replacement therapy (HRT), consisting of the administration of estrogen, alone or combined with progesterone, have been demonstrated to reduce their frequency and severity. Also, systemic estrogen therapy has shown its efficiency in depression, genito-urinary syndrome, cognitive disorders, and postmenopausal migraine syndrome. Non-hormonal treatments, including alimentary supplements, proved their efficacy with low rates of adverse effects. Among nonhormonal therapeutical alternatives, antidepressants such as venlafaxine, paroxetine, or fluoxetine (selective serotonin reuptake inhibitors-SSRI), and the anticonvulsant gabapentin have shown their utility for treating depressive disorders and vasomotor symptoms.

show abstract

Combined Red Clover isoflavones and probiotics potently reduce menopausal vasomotor symptoms

Cited by 54 publications

References 51 publications

Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review

Variation in menopausal vasomotor symptoms outcomes in clinical trials: a systematic review

Influence of Probiotic Supplementation on Climacteric Symptoms in Menopausal Women-a Mini Review

Management Strategies of The Symptomatology and Pathology Associated with Menopause – An Overview

Contact Info

Product

Resources

About